Were Telix (TLX) CEO’s recent share transactions direct or indirect holdings?

The reported Telix share purchases are indirect holdings. The Form 4 classifies ownership as indirect through Elk River Holdings Pty Ltd, and notes that Dr. Christian Behrenbruch is the sole director and shareholder of that entity.

Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy

Filing Impact

(Very High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd MD & Group CEO Dr. Christian Behrenbruch, through Elk River Holdings Pty Ltd, made two open-market purchases of Ordinary Shares. On April 28 and 29, he indirectly bought a combined 67,935 shares at average prices around $14.48 and $14.87 per share, reported in Australian Dollars. After these transactions, his indirect holdings rose to 20,742,935 Ordinary Shares. The filing notes that the reported prices are volume-weighted averages for multiple trades within specified price ranges.

Insights

Telix’s CEO, via Elk River Holdings, made a routine-sized open-market share purchase.

The filing shows Dr. Christian Behrenbruch, MD & Group CEO of Telix Pharmaceuticals Ltd, indirectly purchased 67,935 Ordinary Shares in two open-market transactions at average prices of $14.48 and $14.87 per share, reported in Australian Dollars.

These are straightforward open-market purchases, not option exercises or tax withholdings, and increase his indirect stake to 20,742,935 shares. The Form 4 characterizes the prices as volume-weighted averages across multiple trades within specified ranges on April 28 and April 29, 2026.

The transactions appear as incremental additions to an already large position rather than a transformative change. There is no reference to Rule 10b5-1 trading plans or remaining derivative positions in the disclosure excerpt.

Insider Trade Summary

Net Buyer: 67,935 shares ($996,738)

Net Buy 2 txns

Insider Behrenbruch Christian

Role MD & Group CEO

Bought 67,935 shs ($997K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	33,435	$14.87	$497K
Purchase	Ordinary Shares	34,500	$14.48	$500K

Holdings After Transaction: Ordinary Shares — 20,742,935 shares (Indirect, Elk River Holdings Pty Ltd)

Footnotes (1)

The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.42 - $14.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. The purchase prices are reported in Australian Dollars. Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd. The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.54 - $14.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.

Key Figures

Shares bought 28 Apr 2026: 34,500 shares at $14.48 Shares bought 29 Apr 2026: 33,435 shares at $14.87 Total shares bought: 67,935 shares +3 more

6 metrics

Shares bought 28 Apr 2026 34,500 shares at $14.48 Open-market purchase of Ordinary Shares, average price in AUD

Shares bought 29 Apr 2026 33,435 shares at $14.87 Open-market purchase of Ordinary Shares, average price in AUD

Total shares bought 67,935 shares Net open-market purchases across two days per Form 4 summary

Holdings after transactions 20,742,935 shares Indirect ownership of Ordinary Shares following April 29, 2026 trades

Price range 28 Apr $14.42–$14.58 Footnote price range for multiple trades, reported in AUD

Price range 29 Apr $14.54–$14.72 Footnote price range for multiple trades, reported in AUD

Key Terms

open-market purchase, Ordinary Shares, indirect ownership, average price, +1 more

5 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

indirect ownership financial

"ownership_type: indirect; nature_of_ownership: Elk River Holdings Pty Ltd"

average price financial

"The price reported in Column 4 is an average price."

Australian Dollars financial

"The purchase prices are reported in Australian Dollars."

Form 4 Insider Transactions: What Each Field Means →

05/06/2026 - 09:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behrenbruch Christian

(Last)

(First)

(Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE

3051

(City)

(State)

(Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	MD & Group CEO

2a. Foreign Trading Symbol
[TLX]

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	04/28/2026		P		34,500	A	$14.48⁽¹⁾⁽²⁾	20,709,500	I	Elk River Holdings Pty Ltd⁽³⁾
Ordinary Shares	04/29/2026		P		33,435	A	$14.87⁽²⁾⁽⁴⁾	20,742,935	I	Elk River Holdings Pty Ltd⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.42 - $14.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

2. The purchase prices are reported in Australian Dollars.

3. Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.

4. The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.54 - $14.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.

Remarks:

	/s/ Oliver Newman, on behalf of Dr. Christian Behrenbruch, MD & Group CEO	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Telix Pharmaceuticals (TLX) CEO buy in the latest Form 4?

The Telix Pharmaceuticals MD & Group CEO, Dr. Christian Behrenbruch, indirectly bought 67,935 Ordinary Shares. These were open-market purchases through Elk River Holdings Pty Ltd, increasing his indirect ownership to 20,742,935 shares according to the Form 4 filing.

On what dates did Telix (TLX) CEO Christian Behrenbruch purchase shares?

Dr. Christian Behrenbruch’s indirect open-market purchases occurred on April 28 and April 29, 2026. The Form 4 reports separate transactions on each date, both involving Telix Pharmaceuticals Ordinary Shares acquired through Elk River Holdings Pty Ltd.

What prices did Telix (TLX) CEO pay for the recently acquired shares?

The Form 4 lists average purchase prices of $14.48 and $14.87 per Telix Ordinary Share. Footnotes explain these are volume-weighted averages for multiple trades within price ranges, and that all purchase prices are reported in Australian Dollars.

How many Telix (TLX) shares does the CEO hold after these transactions?

After the reported open-market purchases, Dr. Christian Behrenbruch indirectly holds 20,742,935 Ordinary Shares of Telix Pharmaceuticals. The Form 4 attributes these holdings to Elk River Holdings Pty Ltd, where he is the sole director and shareholder.